<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">34994876</PMID><DateCompleted><Year>2022</Year><Month>01</Month><Day>27</Day></DateCompleted><DateRevised><Year>2022</Year><Month>07</Month><Day>22</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1590-3478</ISSN><JournalIssue CitedMedium="Internet"><Volume>43</Volume><Issue>2</Issue><PubDate><Year>2022</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology</Title><ISOAbbreviation>Neurol Sci</ISOAbbreviation></Journal><ArticleTitle>Perampanel for amyotrophic lateral sclerosis: A systematic review and meta-analysis.</ArticleTitle><Pagination><StartPage>889</StartPage><EndPage>897</EndPage><MedlinePgn>889-897</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s10072-022-05867-6</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Amyotrophic lateral sclerosis (ALS) is a fatal and incurable neurodegenerative disease. There is still no established cost-effective treatment that can improve functional status and survival of ALS patients. Perampanel, by inhibiting neuronal calcium ion influx and preventing dyslocalization of nuclear proteins, has the potential to ameliorate ALS neurodegeneration.</AbstractText><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">This study aims to determine the efficacy and safety of perampanel among ALS patients in terms of improvement in functional status using a review of relevant studies.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">MedLine, Cochrane Central Register for Controlled Trials, Scopus, Embase, Literatura Latino-Americana e do Caribe em Ci&#xea;ncias da Sa&#xfa;de, ClinicalTrials.gov website, and HERDIN databases were searched from inception to August 2021 for relevant studies.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The search yielded 132 articles; 3 studies were included in the analysis. Pooled evidence shows that perampanel compared to placebo significantly improves cortical motor hyperexcitability but not the ALS functional rating scale-revised score. Perampanel is associated with adverse events such as aggression, somnolence, anger, and dysarthria.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">There is no sufficient evidence to support the role of perampanel in improving functional status of ALS patients. Although it can ameliorate motor cortical hyperexcitability, its clinical benefit has not yet been elucidated. Perampanel is not well tolerated among ALS patients as it is associated with adverse events such as aggression, somnolence, anger, and dysarthria. Further studies investigating the role of perampanel early in the ALS disease course, excluding ALS patients with frontotemporal lobe degeneration features and C9ORF72 repeat expansion, and using gradual drug titration schedule are needed to evaluate the potential benefit of perampanel in ALS.</AbstractText><CopyrightInformation>&#xa9; 2022. Fondazione Societ&#xe0; Italiana di Neurologia.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Turalde</LastName><ForeName>Christian Wilson R</ForeName><Initials>CWR</Initials><Identifier Source="ORCID">0000-0001-7237-3728</Identifier><AffiliationInfo><Affiliation>Division of Adult Neurology, Department of Neurosciences, Philippine General Hospital, College of Medicine and Philippine General Hospital, University of the Philippines Manila, Taft Avenue, Ermita, 1000, Manila, Philippines. crturalde@up.edu.ph.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moalong</LastName><ForeName>Kevin Michael C</ForeName><Initials>KMC</Initials><AffiliationInfo><Affiliation>Division of Adult Neurology, Department of Neurosciences, Philippine General Hospital, College of Medicine and Philippine General Hospital, University of the Philippines Manila, Taft Avenue, Ermita, 1000, Manila, Philippines.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Espiritu</LastName><ForeName>Adrian I</ForeName><Initials>AI</Initials><AffiliationInfo><Affiliation>Department of Clinical Epidemiology, College of Medicine, University of the Philippines Manila, Manila, Philippines.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Neurology, Department of Medicine, University of Toronto, Toronto, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Prado</LastName><ForeName>Mario B</ForeName><Initials>MB</Initials><Suffix>Jr</Suffix><AffiliationInfo><Affiliation>Division of Adult Neurology, Department of Neurosciences, Philippine General Hospital, College of Medicine and Philippine General Hospital, University of the Philippines Manila, Taft Avenue, Ermita, 1000, Manila, Philippines.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D016454">Review</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>01</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>Italy</Country><MedlineTA>Neurol Sci</MedlineTA><NlmUniqueID>100959175</NlmUniqueID><ISSNLinking>1590-1874</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009570">Nitriles</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011728">Pyridones</NameOfSubstance></Chemical><Chemical><RegistryNumber>H821664NPK</RegistryNumber><NameOfSubstance UI="C551441">perampanel</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019636" MajorTopicYN="Y">Neurodegenerative Diseases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009570" MajorTopicYN="N">Nitriles</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011728" MajorTopicYN="N">Pyridones</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">Motor neuron disease</Keyword><Keyword MajorTopicYN="N">Perampanel</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>11</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>12</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>1</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>1</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>1</Month><Day>7</Day><Hour>12</Hour><Minute>25</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34994876</ArticleId><ArticleId IdType="doi">10.1007/s10072-022-05867-6</ArticleId><ArticleId IdType="pii">10.1007/s10072-022-05867-6</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Hardiman O, Al-Chalabi A, Chio A et al (2017) Amyotrophic lateral sclerosis. Nat Rev Dis Prim 3:17071. https://doi.org/10.1038/nrdp.2017.71</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrdp.2017.71</ArticleId><ArticleId IdType="pubmed">28980624</ArticleId></ArticleIdList></Reference><Reference><Citation>van Es MA, Hardiman O, Chio A et al (2017) Amyotrophic lateral sclerosis. Lancet 390:2084&#x2013;2098. https://doi.org/10.1016/S0140-6736(17)31287-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(17)31287-4</ArticleId><ArticleId IdType="pubmed">28552366</ArticleId></ArticleIdList></Reference><Reference><Citation>Chi&#xf2; A, Logroscino G, Traynor BJ et al (2013) Global epidemiology of amyotrophic lateral sclerosis: a systematic review of the published literature. Neuroepidemiology 41:118&#x2013;130. https://doi.org/10.1159/000351153</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000351153</ArticleId><ArticleId IdType="pubmed">23860588</ArticleId></ArticleIdList></Reference><Reference><Citation>Foster LA, Salajegheh MK (2019) Motor neuron disease: pathophysiology, diagnosis, and management. Am J Med 132:32&#x2013;37. https://doi.org/10.1016/j.amjmed.2018.07.012</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.amjmed.2018.07.012</ArticleId><ArticleId IdType="pubmed">30075105</ArticleId></ArticleIdList></Reference><Reference><Citation>Blokhuis AM, Groen EJN, Koppers M et al (2013) Protein aggregation in amyotrophic lateral sclerosis. Acta Neuropathol 125:777&#x2013;794. https://doi.org/10.1007/s00401-013-1125-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-013-1125-6</ArticleId><ArticleId IdType="pubmed">23673820</ArticleId><ArticleId IdType="pmc">3661910</ArticleId></ArticleIdList></Reference><Reference><Citation>Gordon P (2013) Amyotrophic lateral sclerosis: an update for 2013 clinical features, pathophysiology, management and therapeutic trials. Aging Dis 04:295&#x2013;310. https://doi.org/10.14336/AD.2013.0400295</Citation><ArticleIdList><ArticleId IdType="doi">10.14336/AD.2013.0400295</ArticleId></ArticleIdList></Reference><Reference><Citation>Heneka MT, Kummer MP, Latz E (2014) Innate immune activation in neurodegenerative disease. Nat Rev Immunol 14:463&#x2013;477. https://doi.org/10.1038/nri3705</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nri3705</ArticleId><ArticleId IdType="pubmed">24962261</ArticleId></ArticleIdList></Reference><Reference><Citation>Kiernan MC, Vucic S, Talbot K et al (2021) Improving clinical trial outcomes in amyotrophic lateral sclerosis. Nat Rev Neurol 17:104&#x2013;118. https://doi.org/10.1038/s41582-020-00434-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41582-020-00434-z</ArticleId><ArticleId IdType="pubmed">33340024</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller RG, Mitchell JD, Moore DH (2012) Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.CD001447.pub3</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/14651858.CD001447.pub3</ArticleId><ArticleId IdType="pubmed">23235617</ArticleId><ArticleId IdType="pmc">7055506</ArticleId></ArticleIdList></Reference><Reference><Citation>Abe K, Aoki M, Tsuji S et al (2017) Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial. Lancet Neurol 16:505&#x2013;512. https://doi.org/10.1016/S1474-4422(17)30115-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(17)30115-1</ArticleId></ArticleIdList></Reference><Reference><Citation>Paganoni S, Macklin EA, Hendrix S et al (2020) Trial of sodium Phenylbutyrate-Taurursodiol for amyotrophic lateral sclerosis. N Engl J Med 383:919&#x2013;930. https://doi.org/10.1056/NEJMoa1916945</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1916945</ArticleId><ArticleId IdType="pubmed">32877582</ArticleId><ArticleId IdType="pmc">9134321</ArticleId></ArticleIdList></Reference><Reference><Citation>Paganoni S, Hendrix S, Dickson SP et al (2021) Long-term survival of participants in the &lt;scp&gt;CENTAUR&lt;/scp&gt; trial of sodium phenylbutyrate-taurursodiol in &lt;scp&gt;amyotrophic lateral sclerosis&lt;/scp&gt;. Muscle Nerve 63:31&#x2013;39. https://doi.org/10.1002/mus.27091</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mus.27091</ArticleId><ArticleId IdType="pubmed">33063909</ArticleId></ArticleIdList></Reference><Reference><Citation>Tavakoli M, Malek M (2001) The cost utility analysis of riluzole for the treatment of amyotrophic lateral sclerosis in the UK. J Neurol Sci 191:95&#x2013;102. https://doi.org/10.1016/S0022-510X(01)00618-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0022-510X(01)00618-9</ArticleId><ArticleId IdType="pubmed">11676998</ArticleId></ArticleIdList></Reference><Reference><Citation>Messori A, Trippoli S, Becagli P, Zaccara G (1999) Cost effectiveness of Riluzole in amyotrophic lateral sclerosis. Pharmacoeconomics 16:153&#x2013;163. https://doi.org/10.2165/00019053-199916020-00004</Citation><ArticleIdList><ArticleId IdType="doi">10.2165/00019053-199916020-00004</ArticleId><ArticleId IdType="pubmed">10539396</ArticleId></ArticleIdList></Reference><Reference><Citation>Yeo CJJ, Simmons Z (2018) Discussing edaravone with the ALS patient: an ethical framework from a U.S. perspective. Amyotroph Lateral Scler Front Degener 19:167&#x2013;172. https://doi.org/10.1080/21678421.2018.1425455</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2018.1425455</ArticleId></ArticleIdList></Reference><Reference><Citation>Sills GJ, Rogawski MA (2020) Mechanisms of action of currently used antiseizure drugs. Neuropharmacology 168:107966. https://doi.org/10.1016/j.neuropharm.2020.107966</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuropharm.2020.107966</ArticleId><ArticleId IdType="pubmed">32120063</ArticleId></ArticleIdList></Reference><Reference><Citation>Akamatsu M, Yamashita T, Hirose N et al (2016) The AMPA receptor antagonist perampanel robustly rescues amyotrophic lateral sclerosis (ALS) pathology in sporadic ALS model mice. Sci Rep 6:28649. https://doi.org/10.1038/srep28649</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep28649</ArticleId><ArticleId IdType="pubmed">27350567</ArticleId><ArticleId IdType="pmc">4923865</ArticleId></ArticleIdList></Reference><Reference><Citation>Oskarsson B, Mauricio EA, Shah JS et al (2021) Cortical excitability threshold can be increased by the AMPA blocker Perampanel in amyotrophic lateral sclerosis. Muscle Nerve 64:215&#x2013;219. https://doi.org/10.1002/mus.27328</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mus.27328</ArticleId><ArticleId IdType="pubmed">34008857</ArticleId></ArticleIdList></Reference><Reference><Citation>Hotait M, Ismail HH, Saab GE, Salameh JS (2021) An open label pilot study of the safety and tolerability of Perampanel in amyotrophic lateral sclerosis. Muscle Nerve 64(4):504&#x2013;508. https://doi.org/10.1002/mus.27385</Citation></Reference><Reference><Citation>Aizawa H, Kato H, Oba K et al (2021) Randomized phase 2 study of perampanel for sporadic amyotrophic lateral sclerosis. J Neurol. https://doi.org/10.1007/s00415-021-10670-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-021-10670-y</ArticleId><ArticleId IdType="pubmed">34191081</ArticleId><ArticleId IdType="pmc">8782807</ArticleId></ArticleIdList></Reference><Reference><Citation>Moher D, Liberati A, Tetzlaff J, Altman DG (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 6:e1000097. https://doi.org/10.1371/journal.pmed.1000097</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pmed.1000097</ArticleId><ArticleId IdType="pubmed">19621072</ArticleId><ArticleId IdType="pmc">2707599</ArticleId></ArticleIdList></Reference><Reference><Citation>Ludolph A, Drory V, Hardiman O et al (2015) A revision of the El Escorial criteria - 2015. Amyotroph Lateral Scler Front Degener 16:291&#x2013;292. https://doi.org/10.3109/21678421.2015.1049183</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/21678421.2015.1049183</ArticleId></ArticleIdList></Reference><Reference><Citation>Nodera H, Izumi Y, Kaji R (2007) New diagnostic criteria of ALS (Awaji criteria). Brain Nerve 59:1023&#x2013;1029. https://doi.org/10.11477/mf.1416100142</Citation><ArticleIdList><ArticleId IdType="doi">10.11477/mf.1416100142</ArticleId><ArticleId IdType="pubmed">17969342</ArticleId></ArticleIdList></Reference><Reference><Citation>Cedarbaum JM, Stambler N, Malta E et al (1999) The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. J Neurol Sci 169:13&#x2013;21. https://doi.org/10.1016/S0022-510X(99)00210-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0022-510X(99)00210-5</ArticleId><ArticleId IdType="pubmed">10540002</ArticleId></ArticleIdList></Reference><Reference><Citation>Mackenzie IRA, Bigio EH, Ince PG et al (2007) Pathological TDP-43 distinguishes sporadic amyotrophic lateral sclerosis from amyotrophic lateral sclerosis with SOD1 mutations. Ann Neurol 61:427&#x2013;434. https://doi.org/10.1002/ana.21147</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.21147</ArticleId><ArticleId IdType="pubmed">17469116</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo C, Ma Y-Y (2021) Calcium Permeable-AMPA receptors and excitotoxicity in neurological disorders. Front Neural Circuits 15:711564. https://doi.org/10.3389/fncir.2021.711564</Citation></Reference><Reference><Citation>Barmada SJ, Skibinski G, Korb E et al (2010) Cytoplasmic mislocalization of TDP-43 is toxic to neurons and enhanced by a mutation associated with familial amyotrophic lateral sclerosis. J Neurosci 30:639&#x2013;649. https://doi.org/10.1523/JNEUROSCI.4988-09.2010</Citation></Reference><Reference><Citation>Lagier-Tourenne C, Polymenidou M, Cleveland DW (2010) TDP-43 and FUS/TLS: emerging roles in RNA processing and neurodegeneration. Hum Mol Genet 19:R46&#x2013;R64. https://doi.org/10.1093/hmg/ddq137</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddq137</ArticleId><ArticleId IdType="pubmed">20400460</ArticleId><ArticleId IdType="pmc">3167692</ArticleId></ArticleIdList></Reference><Reference><Citation>Osawa T, Mizuno Y, Fujita Y et al (2011) Optineurin in neurodegenerative diseases. Neuropathology 31:569&#x2013;574. https://doi.org/10.1111/j.1440-1789.2011.01199.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1440-1789.2011.01199.x</ArticleId><ArticleId IdType="pubmed">21284751</ArticleId></ArticleIdList></Reference><Reference><Citation>Renton AE, Majounie E, Waite A et al (2011) A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron 72:257&#x2013;268. https://doi.org/10.1016/j.neuron.2011.09.010</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2011.09.010</ArticleId><ArticleId IdType="pubmed">21944779</ArticleId><ArticleId IdType="pmc">3200438</ArticleId></ArticleIdList></Reference><Reference><Citation>Deng H-X, Chen W, Hong S-T et al (2011) Mutations in UBQLN2 cause dominant X-linked juvenile and adult-onset ALS and ALS/dementia. Nature 477:211&#x2013;215. https://doi.org/10.1038/nature10353</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature10353</ArticleId><ArticleId IdType="pubmed">21857683</ArticleId><ArticleId IdType="pmc">3169705</ArticleId></ArticleIdList></Reference><Reference><Citation>Elden AC, Kim H-J, Hart MP et al (2010) Ataxin-2 intermediate-length polyglutamine expansions are associated with increased risk for ALS. Nature 466:1069&#x2013;1075. https://doi.org/10.1038/nature09320</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature09320</ArticleId><ArticleId IdType="pubmed">20740007</ArticleId><ArticleId IdType="pmc">2965417</ArticleId></ArticleIdList></Reference><Reference><Citation>Jaiswal MK (2017) Riluzole but not melatonin ameliorates acute motor neuron degeneration and moderately inhibits SOD1-mediated excitotoxicity induced disrupted mitochondrial Ca2+ signaling in amyotrophic lateral sclerosis. Front Cell Neurosci 10:295. https://doi.org/10.3389/fncel.2016.00295</Citation></Reference><Reference><Citation>Keon M, Musrie B, Dinger M et al (2021) Destination amyotrophic lateral sclerosis. Front Neurol 12:596006. https://doi.org/10.3389/fneur.2021.596006</Citation></Reference><Reference><Citation>Youn SE, Kim SH, Ko A et al (2018) Adverse events during perampanel adjunctive therapy in intractable epilepsy. J Clin Neurol 14:296. https://doi.org/10.3988/jcn.2018.14.3.296</Citation><ArticleIdList><ArticleId IdType="doi">10.3988/jcn.2018.14.3.296</ArticleId><ArticleId IdType="pubmed">29971974</ArticleId><ArticleId IdType="pmc">6031997</ArticleId></ArticleIdList></Reference><Reference><Citation>Rugg-Gunn F (2014) Adverse effects and safety profile of perampanel: a review of pooled data. Epilepsia 55:13&#x2013;15. https://doi.org/10.1111/epi.12504</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/epi.12504</ArticleId><ArticleId IdType="pubmed">24400692</ArticleId></ArticleIdList></Reference><Reference><Citation>Abramzon YA, Fratta P, Traynor BJ, Chia R (2020) The overlapping genetics of amyotrophic lateral sclerosis and frontotemporal dementia. Front Neurosci 14:42. https://doi.org/10.3389/fnins.2020.00042</Citation></Reference><Reference><Citation>Ling S-C, Polymenidou M, Cleveland DW (2013) Converging mechanisms in ALS and FTD: disrupted RNA and protein homeostasis. Neuron 79:416&#x2013;438. https://doi.org/10.1016/j.neuron.2013.07.033</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2013.07.033</ArticleId><ArticleId IdType="pubmed">23931993</ArticleId><ArticleId IdType="pmc">4411085</ArticleId></ArticleIdList></Reference><Reference><Citation>Montuschi A, Iazzolino B, Calvo A et al (2015) Cognitive correlates in amyotrophic lateral sclerosis: a population-based study in Italy. J Neurol Neurosurg Psychiatry 86:168&#x2013;173. https://doi.org/10.1136/jnnp-2013-307223</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2013-307223</ArticleId><ArticleId IdType="pubmed">24769471</ArticleId></ArticleIdList></Reference><Reference><Citation>Gotovac K, NikolacPerkovi&#x107; M, Pivac N, Borove&#x10d;ki F (2016) Biomarkers of aggression in dementia. Prog Neuro-Psychopharmacology Biol Psychiatry 69:125&#x2013;130. https://doi.org/10.1016/j.pnpbp.2016.03.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pnpbp.2016.03.002</ArticleId></ArticleIdList></Reference><Reference><Citation>Grochmal-Bach B, Bidzan L, Pachalska M et al (2009) Aggressive and impulsive behaviors in Frontotemporal dementia and Alzheimer&#x2019;s disease. Med Sci Monit 15:CR248-54</Citation><ArticleIdList><ArticleId IdType="pubmed">19396041</ArticleId></ArticleIdList></Reference><Reference><Citation>Byrne S, Elamin M, Bede P et al (2012) Cognitive and clinical characteristics of patients with amyotrophic lateral sclerosis carrying a C9orf72 repeat expansion: a population-based cohort study. Lancet Neurol 11:232&#x2013;240. https://doi.org/10.1016/S1474-4422(12)70014-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(12)70014-5</ArticleId><ArticleId IdType="pubmed">22305801</ArticleId><ArticleId IdType="pmc">3315021</ArticleId></ArticleIdList></Reference><Reference><Citation>Bersano E, Sarnelli MF, Solara V et al (2020) Decline of cognitive and behavioral functions in amyotrophic lateral sclerosis: a longitudinal study. Amyotroph Lateral Scler Front Degener 21:373&#x2013;379. https://doi.org/10.1080/21678421.2020.1771732</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2020.1771732</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>